Turn Therapeutics Inc. filed a Current Report on Form 8-K dated November 10, 2026, to furnish an updated investor presentation. The document, filed with the U.S. Securities and Exchange Commission, provides an overview of the company's pipeline and clinical development progress.
The presentation details the company's lead candidate, GX-03, a precision, non-systemic immunomodulation therapy targeting IL-36 and key downstream cytokines. The company states that the therapy is designed for the treatment of atopic dermatitis (AD), with an initial focus on moderate to severe cases. According to the filing, over 200,000 patients have received GX-03 with zero reported adverse events.
The filing outlines the current status of the Phase 2 clinical trial for moderate to severe AD. Topline results from this trial are expected in the first quarter of 2027. The company also projects the initiation of a Phase 3 trial for AD in mid-2027, with a potential commercial launch targeted for 2029.
In addition to GX-03, the presentation highlights other pipeline programs. A Phase 2a trial for Hidradenitis Suppurativa is scheduled to begin in Q1 2027, and a Phase 3 trial for Onychomycosis is set to begin in Q2 2027. The company also notes that it has out-licensed its FDA-cleared antimicrobial surgical gauze and sterile collagen powder, with the latter subject to $70 million in potential milestones.
The filing includes a list of risk factors associated with the company's business, including industry competition, economic factors, regulatory challenges, and uncertainties in clinical development. The company emphasizes that forward-looking statements in the presentation are subject to significant risks and uncertainties and that actual results may differ materially.
